Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

BACKGROUND The NHLBI Post Coronary Artery Bypass Graft trial (Post CABG) showed that aggressive compared with moderate lowering of low-density lipoprotein-cholesterol (LDL-C) decreased obstructive changes in saphenous vein grafts (SVGs) by 31%.1 Using lovastatin and cholestyramine when necessary, the annually determined mean LDL-C level ranged from 93 to 97 mg/dL in aggressively treated patients and from 132 to 136 mg/dL in the others (P<0.001). METHODS AND RESULTS The present study evaluated the treatment effect in subgroups defined by age, gender, and selected coronary heart disease (CHD) risk factors, ie, smoking, hypertension, diabetes mellitus, high-density lipoprotein cholesterol (HDL-C) <35 mg/dL, and triglyceride serum levels >/=200 mg/dL at baseline. As evidenced by similar odds ratio estimates of progression (lumen diameter decrease >/=0.6 mm) and lack of interactions with treatment, a similar beneficial effect of aggressive lowering was observed in elderly and young patients, in women and men, in patients with and without smoking, hypertension, or diabetes mellitus, and those with and without borderline high-risk triglyceride serum levels. The change in minimum lumen diameter was in the same direction for all subgroup categories, without significant interactions with treatment. CONCLUSIONS Aggressive LDL-C lowering delays progression of atherosclerosis in SVGs irrespective of gender, age, and certain risk factors for CHD.

[1]  P. Renshaw,et al.  [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.

[2]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[3]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[4]  B. Hoogwerf,et al.  Delayed progression of atherosclerosis in coronary bypass grafts is similar in women compared to men following aggressive cholesterol lowering despite more frequent risk factors: post CABG trial , 1998 .

[5]  O. Faergeman,et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[6]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[7]  S. Cobbe.  Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. , 1997, The American journal of cardiology.

[8]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[9]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[10]  C. White,et al.  The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes , 1996 .

[11]  Johan H. C. Reiber,et al.  Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis , 1996, Developments in Cardiovascular Medicine.

[12]  J. Kjekshus,et al.  Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). , 1995, The American journal of cardiology.

[13]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[14]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[15]  R. Krauss,et al.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.

[16]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[17]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[18]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[19]  D. Ornish.  Can lifestyle changes reverse coronary heart disease? , 1993, World review of nutrition and dietetics.

[20]  R. Varco,et al.  Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias. , 1992, Annals of surgery.

[21]  B. Lewis,et al.  Effects on Coronary Artery Disease of Lipid-Lowering Diet, or Diet Plus Cholestyramine, in the St. Thomasʼ Artherosclerosis Regression Study (STARS) , 1992 .

[22]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results: Effect of Patient Characteristics on Lovastatin‐Induced Changes in Plasma Concentrations of Lipids and Lipoproteins , 1992, Circulation.

[23]  C. Isles,et al.  Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men , 1992, The Lancet.

[24]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[25]  T. Manolio,et al.  Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. , 1992, Annals of epidemiology.

[26]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. , 1991, The American journal of medicine.

[27]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[28]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[29]  J P Matts,et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.

[30]  K. Gould,et al.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.

[31]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[32]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[33]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[34]  W. Kannel,et al.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. , 1979, Annals of internal medicine.